Intrarosa

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Prasterone

Available from:

Endoceutics S.A.

ATC code:

G03XX01

INN (International Name):

prasterone

Therapeutic group:

Drugi spolni hormoni in zdravila genitalni sistem

Therapeutic area:

Postmenopavza

Therapeutic indications:

Intrarosa je indicirano za zdravljenje vulve in vaginalne atrofije v menopavzi, ki imajo zmerno do hudo simptomi.

Product summary:

Revision: 6

Authorization status:

Pooblaščeni

Authorization date:

2018-01-08

Patient Information leaflet

                                19
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Endoceutics S.A.
Rue Belliard 40
1040 Bruselj
Belgija
12.
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/17/1255/001
13.
ŠTEVILKA SERIJE<, ENOTNE OZNAKE DAROVANJA IN IZDELKOV>
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
_ _
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Intrarosa
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
20
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOTI
1.
IME ZDRAVILA
_ _
Intrarosa 6,5 mg vaginalne globule
prasteron
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Endoceutics
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE<, ENOTNE OZNAKE DAROVANJA IN IZDELKOV>
Lot
5.
DRUGI PODATKI
21
PODATKI NA ZUNANJI OVOJNINI
NOTRANJA ŠKATLA
1.
IME ZDRAVILA
Intrarosa 6,5 mg vaginalne globule
prasteron
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena vaginalna globula vsebuje 6,5 mg prasterona.
3.
SEZNAM POMOŽNIH SNOVI
trda mast (adeps solidus)
4.
FARMACEVTSKA OBLIKA IN VSEBINA
vaginalna globula
28 vaginalnih globul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
vaginalna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C.
Ne zamrzujte.
22
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Endoceutics S.A.
Rue Belliard 40
1040 Bruselj
Belgija
12.
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/17/1255/001
13.
ŠTEVIL
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Intrarosa 6,5 mg vaginalne globule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena vaginalna globula vsebuje 6,5 mg prasterona (prasteron.).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Vaginalne globule
Bela do belkasta globula v obliki naboja, dolga približno 28 mm in s
premerom 9 mm na najširšem
delu.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Intrarosa je indicirano za zdravljenje atrofije vulve in
vagine pri ženskah po menopavzi, ki
imajo zmerne do hude simptome.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek je 6,5 mg prasterona (ena globula) enkrat na dan,
pred spanjem.
Za zdravljenje pomenopavznih simptomov se naj zdravilo Intrarosa uvede
šele, ko simptomi negativno
vplivajo na kakovost življenja. V vseh primerih je treba vsaj na
vsakih šest mesecev natančno oceniti
koristi in tveganja ter zdravljenje z zdravilom Intrarosa nadaljevati,
dokler so koristi večje od tveganj.
Če bolnica pozabi uporabiti odmerek, naj ga uporabi takoj, ko se na
to spomni. Če pa naslednji
odmerek sledi prej kot v 8 urah, naj bolnica zamujeno globulo
preskoči. Ne sme uporabiti dveh globul,
da bi nadomestila zamujeni odmerek.
_ _
_Posebne skupine bolnikov _
_ _
_Starejši _
Pri starejših bolnicah odmerka ni treba prilagajati.
_ _
_Bolnice z okvaro ledvic in/ali jeter _
Ker zdravilo Intrarosa deluje lokalno v vagini, prilagajanje odmerka
pri ženskah po menopavzi, ki
imajo okvaro ledvic ali jeter ali katero koli drugo sistemsko
anomalijo ali bolezen, ni potrebno.
_ _
_Pediatrična populacija _
Uporaba zdravila Intrarosa za indikacijo atrofije vulve in vagine
zaradi menopavze ne pride v poštev
pri deklicah katere koli starosti.
3
Način uporabe
Vaginalna uporaba
Zdravilo Intrarosa se lahko vstavi v vagino s prstom ali z
aplikatorjem, ki je v pakiranju.
Vaginalno globulo je treba v vagino vstaviti tako daleč, kolikor gre
brez sile.
Pri vstavljanju z aplikatorjem je treba upoštevati naslednje ko
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-01-2024
Public Assessment Report Public Assessment Report Bulgarian 14-02-2018
Patient Information leaflet Patient Information leaflet Spanish 15-01-2024
Public Assessment Report Public Assessment Report Spanish 14-02-2018
Patient Information leaflet Patient Information leaflet Czech 15-01-2024
Public Assessment Report Public Assessment Report Czech 14-02-2018
Patient Information leaflet Patient Information leaflet Danish 15-01-2024
Public Assessment Report Public Assessment Report Danish 14-02-2018
Patient Information leaflet Patient Information leaflet German 15-01-2024
Public Assessment Report Public Assessment Report German 14-02-2018
Patient Information leaflet Patient Information leaflet Estonian 15-01-2024
Public Assessment Report Public Assessment Report Estonian 14-02-2018
Patient Information leaflet Patient Information leaflet Greek 15-01-2024
Public Assessment Report Public Assessment Report Greek 14-02-2018
Patient Information leaflet Patient Information leaflet English 15-01-2024
Public Assessment Report Public Assessment Report English 14-02-2018
Patient Information leaflet Patient Information leaflet French 15-01-2024
Public Assessment Report Public Assessment Report French 14-02-2018
Patient Information leaflet Patient Information leaflet Italian 15-01-2024
Public Assessment Report Public Assessment Report Italian 14-02-2018
Patient Information leaflet Patient Information leaflet Latvian 15-01-2024
Public Assessment Report Public Assessment Report Latvian 14-02-2018
Patient Information leaflet Patient Information leaflet Lithuanian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-01-2024
Public Assessment Report Public Assessment Report Lithuanian 14-02-2018
Patient Information leaflet Patient Information leaflet Hungarian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 15-01-2024
Public Assessment Report Public Assessment Report Hungarian 14-02-2018
Patient Information leaflet Patient Information leaflet Maltese 15-01-2024
Public Assessment Report Public Assessment Report Maltese 14-02-2018
Patient Information leaflet Patient Information leaflet Dutch 15-01-2024
Public Assessment Report Public Assessment Report Dutch 14-02-2018
Patient Information leaflet Patient Information leaflet Polish 15-01-2024
Public Assessment Report Public Assessment Report Polish 14-02-2018
Patient Information leaflet Patient Information leaflet Portuguese 15-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 15-01-2024
Public Assessment Report Public Assessment Report Portuguese 14-02-2018
Patient Information leaflet Patient Information leaflet Romanian 15-01-2024
Public Assessment Report Public Assessment Report Romanian 14-02-2018
Patient Information leaflet Patient Information leaflet Slovak 15-01-2024
Public Assessment Report Public Assessment Report Slovak 14-02-2018
Patient Information leaflet Patient Information leaflet Finnish 15-01-2024
Public Assessment Report Public Assessment Report Finnish 14-02-2018
Patient Information leaflet Patient Information leaflet Swedish 15-01-2024
Public Assessment Report Public Assessment Report Swedish 14-02-2018
Patient Information leaflet Patient Information leaflet Norwegian 15-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 15-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 15-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 15-01-2024
Patient Information leaflet Patient Information leaflet Croatian 15-01-2024
Public Assessment Report Public Assessment Report Croatian 14-02-2018

Search alerts related to this product

View documents history